



Leader in Targeted Protein Modulation

Discovery of Orally Active, Brain-Penetrant, Targeted Protein Degraders

5th Annual TPD Summit

Boston, MA

October 26th, 2022

Important Notice and Disclaimers

This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “outlook,” “plan,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to Nurix Therapeutics, Inc. (“Nurix”, the “Company,” “we,” “us” or “our”), may identify forward-looking statements. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding our future financial or business plans; our future performance, prospects and strategies; future conditions, trends, and other financial and business matters; our current and prospective drug candidates; the planned timing and conduct of the clinical trial programs for our drug candidates; the planned timing for the provision of clinical updates and initial findings from our clinical studies; the potential advantages of our DELigase™ platform and drug candidates; the extent to which our scientific approach and DELigase™ platform may potentially address a broad range of diseases; the extent animal model data predicts human efficacy; and the timing and success of the development and commercialization of our current and anticipated drug candidates. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes the expectations and assumptions reflected in such forward-looking statements are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) risks and uncertainties related to Nurix’s ability to advance its drug candidates, obtain regulatory approval of and ultimately commercialize its drug candidates; (ii) the timing and results of clinical trials and preclinical studies; (iii) Nurix’s ability to fund development activities and achieve development goals; (iv) the impact of the COVID-19 pandemic on Nurix’s business, clinical trials, financial condition, liquidity and results of operations; (v) Nurix’s ability to protect intellectual property and (vi) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2022, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this presentation speak only as of the date of this presentation, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal estimates and research are reliable, such estimates and research have not been verified by any independent source.

Nurix Drugs Engage Ligases for the Treatment of Cancer

Targeted Protein Modulation: $TPM = TPD + TPE$

A Powerful
Cellular System



Targeted Protein
Elevation
(TPE)

Harness ligases
to decrease
specific protein levels

Inhibit ligases
to increase
specific protein levels

Targeted Protein
Degradation
(TPD)


Ubiquitin is ligated to
target proteins to tag
them for degradation by
the proteasome

Nurix Is Advancing Four Wholly Owned Clinical Programs with a Deep Pipeline of Proprietary and Partnered Novel Targets


MOA	Drug Program	Target/ Delivery	Therapeutic Area	Pre-Clinical	Phase 1	Phase 2	Phase 3
TPD	NX-2127 Degradator	BTK-IKZF <i>Oral</i>	B-Cell Malignancies				
	NX-5948 Degradator	BTK <i>Oral</i>	B-Cell Malignancies				
TPE	NX-1607 Inhibitor	CBL-B <i>Oral</i>	Immuno-Oncology				
	DeTIL-0255 Cell Therapy	Adoptive Cell Therapy <i>Ex vivo CBL-B Inhibition</i>	Gynecologic Malignancies				
TPM	Wholly owned	5 targets	Multiple				
TPD	Gilead Sciences	5 targets	Multiple				
TPD	Sanofi	5 targets	Multiple				

MOA, Mechanism of action; TPD, Targeted Protein Degradation; TPE, Targeted Protein Elevation; TPM, Targeted Protein Modulation

NX-5948 Promotes Proteasomal Degradation of BTK




BTK Regulates Signaling Pathways that Contribute to B Cell Malignancies and Autoimmunity



- BTK transduces signals downstream of the B cell receptor, toll-like receptors, and Fc receptors in B cells and myeloid cells
- BTK regulates B cell maturation, autoantibody production, and antigen presentation to T cells
- BTK regulates immune-complex mediated activation of myeloid cells which directly damages tissues
- BTK degraders that cross the blood brain barrier (BBB) may have therapeutic advantage in CNS lymphoma or autoimmune diseases such as MS


NX-5948 is a Potent and Rapid BTK Degradator

Dose Titration on Primary Human B cells



N=3 independent donors
SEM error bars are smaller than symbols

Degradation Time-Course




Ramos human Burkitt's lymphoma B cells
incubated with 10 nM NX-5948

- Robust BTK degradation observed in primary human B cells after 4 hours of NX-5948 treatment
- BTK degradation is observed within 1 hour and is complete within 2 hours in Ramos cells


A Single Oral Dose of NX-5948 Promotes Rapid and Complete BTK Degradation in Mouse and NHP B cells

BTK Levels in Mouse Circulating B Cells



□ Vehicle ● NX-5948 10 mg/kg
◆ NX-5948 3 mg/kg ■ NX-5948 30 mg/kg


BTK Levels in Cyno Circulating B Cells



● NX-5948 10 mg/kg
■ NX-5948 100 mg/kg

- In mice, BTK levels increased 24 hours after dosing from BTK resynthesis
- In cynomolgus monkeys, BTK levels remained suppressed at 24 hours


Increasing BTK Degradation by NX-5948 Correlates with Significant Tumor Growth Inhibition




Treatment	Oral gavage dose (mg/kg)	% BTK degradation in circulating B cells	% BTK degradation in TMD8 tumor tissue	% TGI vs Vehicle (Day 26)	P value vs Vehicle
Vehicle	0	0.0±3.7	0.0±4.7	N/A	N/A
NX-5948	3	50.5±1.9	69.2±0.9	54%	0.0025
	10	63.5±1.1	82.4±2.1	100%	<0.0001
	30	79.0±3.1	90.5±0.5	100%	<0.0001
Ibrutinib	30	N/A	N/A	57%	0.0015

A Single Oral Dose of NX-5948 to Mice Results in Dose-Dependent CNS Exposure


NX-5948 Exposure in Mouse Brain



NX-5948 Exposure in Plasma




NX-5948 Mouse Brain/Plasma Ratio



NX-5948 Degrades BTK in Microglia and Macrophage in Brains of Naïve Mice

NX-5948 administered orally QD x 3 days to naïve C57BL/6J mice.
BTK levels assessed 8 h after 3rd dose by flow cytometry.




- NX-5948 drives dose-dependent BTK degradation in cells isolated from brains
- Magnitude of BTK degradation depends on dose and cell type

Oral Administration of NX-5948 Degrades BTK in Tumor Cells and Prolongs Survival in a Mouse Model of CNS Lymphoma


5 x 10⁵ TMD8 cells implanted by intracranial injection on Day 0
NX-5948 administered orally QD Days 1-11 (left) or Days 1-54 (right)
BTK levels assessed 24 h after the 11th dose by flow cytometry

BTK Levels In TMD8



****p < 0.0001 compared to vehicle control (Welch's t-test)

Long-Term Survival




****p < 0.0001 compared to vehicle control (Log-rank test)

Comparison of NX-5948 to Ibrutinib in Antibody-Dependent EAE model

Group	N	Treatment	Dose (mpk)	Regimen
1	12	Vehicle	N/A	N/A
2	12	FTY720	3	Oral, QD, Days -1 to 22
3	12	Ibrutinib	10	
4	12	Ibrutinib	30	
5	12	NX-5948	10	
6	12	NX-5948	30	


- EAE is induced by immunization with full-length human MOG (myelin oligodendrocyte glycoprotein) to initiate an autoimmune reaction similar to multiple sclerosis
- This particular EAE model is dependent upon B cells, T cells, anti-MOG Ab, and myeloid cells
- BTK functions downstream of the B cell Receptor to promote B cell activation, produce anti-MOG antibodies, and present antigen to autoreactive T cells
- BTK also functions downstream of the Fc Receptor to activate myeloid cells such as microglia against anti-MOG antibodies bound to myelin, promoting demyelination




NX-5948 Improves EAE Clinical Scores and Provides Greater Benefit than Ibrutinib

Disease initiated on Day 0 with full-length human MOG₁₋₁₂₅ and pertussis toxin
Daily oral administration of NX-5948 or Ibrutinib Days -1 to 22

EAE Severity




NX-5948 Treated Groups Have Trends of Lower α MOG Antibody Titers





Statistical comparison vs. vehicle by One-Way ANOVA with Dunnett's multiple comparison test (significance not reached)

NX-5948 Improved Histological Findings Associated with EAE More Strongly Than Ibrutinib



- NX-5948 dramatically reduced inflammation, demyelination, and apoptosis in the spinal cords of treated mice
- Degradation of BTK in brain-resident myeloid cells may contribute to the superior activity of NX-5948 over ibrutinib

How Do We Design Degraders that Cross the Blood Brain Barrier?



- The BBB is a selective barrier that protects the brain from harmful compounds and precisely regulates its microenvironment
- The CNS multiparameter optimization score (MPO score) defines chemical properties that are optimal for CNS therapeutic agents


CNS MPO Properties and Parameter Ranges

Property	More Desirable	Less Desirable
ClogP	≤ 3	> 5
ClogD	≤ 2	> 4
MW	≤ 360	> 500
TPSA	40 to 90	$\leq 20, > 120$
HBD	≤ 1	> 3
pKa	≤ 8	> 10

Each property assigned a score from 0.0 to 1.0 and summed. 74% of marketed CNS drugs had an MPO score ≥ 4.0 (Wager, et al., *ACS Chem Neuro*, 2010)

- Determining the parameters and characteristics that predict CNS exposure of degraders are of high interest

Nurix Has Established a Testing Funnel for Identifying Degraders that Cross the Blood Brain Barrier



Potent Orally-Active Degraders of an Undisclosed Target Were Identified and Selected for CNS Evaluation


Goal: Develop degraders that suppress T cell function for treatment of autoimmune and inflammatory diseases

- Target Expressed in T cells and other immune cells

	NRX-001	NRX-002	NRX-003
Cellular Degradation (HiBiT)	DC ₅₀ : < 0.01 nM D _{max} : 88%	DC ₅₀ : 0.62 nM D _{max} : 84%	DC ₅₀ : < 0.01 nM D _{max} : 88%
In Vitro Plasma Protein Binding (Mouse, %)	95%	97%	96%
In Vivo Clearance (Mouse, mL/min/kg)	2.7	14.2	20.7
Oral bioavailability (Mouse, % F at 10 mg/kg)	26%	43%	32%
In Vivo PD Mouse, PO, 30 mg/kg, 24 h (% Degradation in Splenocytes)	88%	74%	92%
CNS MPO Score (Range 0 – 6, ≥ 4 is desirable range)	1.2	1.5	2.4


Degraders had a range of CNS exposure, despite low CNS MPO scores

Single oral dose administered to mice at 150 mg/kg



Lead Compound was Selected Based on Performance in a T Cell Dependent EAE Model

Disease initiated on Day 0 with human MOG₃₅₋₅₅ peptide and pertussis toxin
Daily oral administration of compounds beginning Day -1



- Ongoing characterization of the PK/PD relationship will include analysis of brain exposure, target degradation, and phenotype of immune cells that infiltrate the brain during the course of disease

Summary

- Discovery of oral, CNS-penetrant, targeted protein degraders is enabled by a testing funnel that evaluates ADME, potency, exposures, and efficacy in a step-wise process
- NX-5948 is an oral CNS-penetrant, targeted protein degrader of BTK
 - Degrades BTK in primary human B cells ($DC_{50} = 0.034$ nM), cancer cell lines, and tumor xenografts
 - Promotes BTK degradation in microglia and periventricular macrophage of naïve mice
- NX-5948 significantly degrades BTK in brain-resident tumor cells and extends survival in a mouse model of CNS lymphoma
- NX-5948 provides superior activity to ibrutinib in an antibody dependent model of EAE
- Using the established testing funnel, a targeted protein degrader with CNS exposure was identified that has superior efficacy in a T-cell driven model of EAE
 - Additional characteristics beyond CNS MPO scores may be needed to predict CNS exposure for degraders



Thank you
Nurix Therapeutics